BGI Genomics Co Ltd (SHE:300676) — Market Cap & Net Worth
Market Cap & Net Worth: BGI Genomics Co Ltd (300676)
BGI Genomics Co Ltd (SHE:300676) has a market capitalization of $2.08 Billion (CN¥14.22 Billion) as of June 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #6194 globally and #1302 in its home market, demonstrating a 1.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BGI Genomics Co Ltd's stock price CN¥33.99 by its total outstanding shares 418317075 (418.32 Million). Review BGI Genomics Co Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
BGI Genomics Co Ltd Market Cap History: 2017 to 2026
BGI Genomics Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $12.29 Billion to $2.08 Billion (6.76% CAGR).
Index Memberships
BGI Genomics Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.39 Trillion | 0.15% | #83 of 100 |
Weight: BGI Genomics Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BGI Genomics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BGI Genomics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.75x
BGI Genomics Co Ltd's market cap is 0.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $12.29 Billion | $2.10 Billion | $398.09 Million | 5.86x | 30.86x |
| 2018 | $3.56 Billion | $2.54 Billion | $386.65 Million | 1.40x | 9.22x |
| 2019 | $4.09 Billion | $2.80 Billion | $276.33 Million | 1.46x | 14.79x |
| 2020 | $7.65 Billion | $8.40 Billion | $2.09 Billion | 0.91x | 3.66x |
| 2021 | $5.24 Billion | $6.77 Billion | $1.46 Billion | 0.77x | 3.59x |
| 2022 | $3.10 Billion | $7.05 Billion | $802.77 Million | 0.44x | 3.86x |
| 2023 | $2.93 Billion | $4.35 Billion | $92.90 Million | 0.67x | 31.54x |
| 2024 | $2.57 Billion | $3.87 Billion | -$902.69 Million | 0.66x | N/A |
| 2025 | $2.78 Billion | $3.71 Billion | -$616.66 Million | 0.75x | N/A |
Competitor Companies of 300676 by Market Capitalization
Companies near BGI Genomics Co Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to BGI Genomics Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
BGI Genomics Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, BGI Genomics Co Ltd's market cap moved from $12.29 Billion to $ 2.08 Billion, with a yearly change of 6.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.08 Billion | -25.07% |
| 2025 | CN¥2.78 Billion | +8.08% |
| 2024 | CN¥2.57 Billion | -12.31% |
| 2023 | CN¥2.93 Billion | -5.54% |
| 2022 | CN¥3.10 Billion | -40.84% |
| 2021 | CN¥5.24 Billion | -31.50% |
| 2020 | CN¥7.65 Billion | +87.25% |
| 2019 | CN¥4.09 Billion | +14.70% |
| 2018 | CN¥3.56 Billion | -71.00% |
| 2017 | CN¥12.29 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of BGI Genomics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.08 Billion USD |
| MoneyControl | $2.08 Billion USD |
| MarketWatch | $2.08 Billion USD |
| marketcap.company | $2.08 Billion USD |
| Reuters | $2.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more